Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients

Cancer. 1986 Dec 15;58(12):2576-8. doi: 10.1002/1097-0142(19861215)58:12<2576::aid-cncr2820581203>3.0.co;2-6.

Abstract

Ninety-six patients with disseminated malignant melanoma received thrice weekly intramuscular injections of leukocyte A recombinant interferon (rIFN-alpha A, Roferon-A, Hoffmann La Roche) at doses of 12 X 10(6) U/m2 or 50 X 10(6) U/m2 with or without cimetidine as an immunorestorative agent. Four patients, two with prior chemotherapy, demonstrated either a complete response (3 months, soft tissue metastasis) or exceptionally durable response durations (months) of 29+ (soft tissue; lung lesion), 31+ (soft tissue), and 35+ (soft tissue; liver lesions). None of these patients had particularly characteristic clinical parameters. As noted previously, using chemotherapy, a small proportion of patients with advanced malignant melanoma, despite prior therapy, may achieve prolonged objective regression with rIFN-alpha A.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Drug Evaluation
  • Female
  • Humans
  • Interferon Type I / therapeutic use*
  • Male
  • Melanoma / therapy*
  • Middle Aged
  • Neoplasm Metastasis
  • Recombinant Proteins / therapeutic use*
  • Skin Neoplasms / therapy*

Substances

  • Interferon Type I
  • Recombinant Proteins